“Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption”, Mediterr J Hematol Infect Dis, vol. 13, no. 1, p. e2021022, Feb. 2021, doi: 10.4084/mjhid.2021.022.